{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:20:46Z","timestamp":1793370046127,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Shandong Provincial Natural Science Foundation","doi-asserted-by":"crossref","award":["ZR2023MH058"],"award-info":[{"award-number":["ZR2023MH058"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the ECCM Program of Clinical Research Center of Shandong University","award":["2021SDUCRCE001"],"award-info":[{"award-number":["2021SDUCRCE001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-025-00332-7","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:03:20Z","timestamp":1751871800000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluating cardioprotective strategies for anthracycline-induced cardiotoxicity in breast cancer: insights from a systematic review and network meta-analysis"],"prefix":"10.1186","volume":"11","author":[{"given":"Runyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"332_CR1","doi-asserted-by":"publisher","unstructured":"Herbst RS, Bajorin DF, Bleiberg H et al. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol. 2006; https:\/\/doi.org\/10.1200\/jco.2005.04.8678.","DOI":"10.1200\/jco.2005.04.8678"},{"key":"332_CR2","doi-asserted-by":"publisher","unstructured":"DeSantis CE, Ma J, Gaudet MM et al. Breast cancer statistics, 2019. CA: a cancer journal for clinicians. 2019; https:\/\/doi.org\/10.3322\/caac.21583.","DOI":"10.3322\/caac.21583"},{"key":"332_CR3","doi-asserted-by":"publisher","unstructured":"Roth GA, Mensah GA, Johnson CO et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990\u20132019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020; https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010.","DOI":"10.1016\/j.jacc.2020.11.010"},{"key":"332_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.023","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.023.","journal-title":"Ann Oncol"},{"key":"332_CR5","doi-asserted-by":"publisher","unstructured":"Walli-Attaei M, Rosengren A, Rangarajan S et al. Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study. Lancet (London, England). 2022; https:\/\/doi.org\/10.1016\/s0140-6736(22)01441-6.","DOI":"10.1016\/s0140-6736(22)01441-6"},{"key":"332_CR6","doi-asserted-by":"publisher","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). European heart journal. 2022; https:\/\/doi.org\/10.1093\/eurheartj\/ehac244.","DOI":"10.1093\/eurheartj\/ehac244"},{"key":"332_CR7","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.196","author":"M Akpek","year":"2015","unstructured":"Akpek M, Ozdogru I, Sahin O, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015. https:\/\/doi.org\/10.1002\/ejhf.196.","journal-title":"Eur J Heart Fail"},{"key":"332_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.10.001","author":"MK Davis","year":"2019","unstructured":"Davis MK, Villa D, Tsang TSM, et al. Effect of Eplerenone on Diastolic Function in Women Receiving Anthracycline-Based Chemotherapy for Breast Cancer. JACC CardioOncology. 2019. https:\/\/doi.org\/10.1016\/j.jaccao.2019.10.001.","journal-title":"JACC CardioOncology"},{"key":"332_CR9","unstructured":"Liu L, Liu ZZ, Liu YY, Zheng ZD, Liang XF, Han YL, Xie XD. Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer [in Chinese]. Zhonghua Zhong Liu Za Zhi. 2013;35(12):936\u201340. PMID: 24506965."},{"key":"332_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw022","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016. https:\/\/doi.org\/10.1093\/eurheartj\/ehw022.","journal-title":"Eur Heart J"},{"key":"332_CR11","doi-asserted-by":"publisher","DOI":"10.33963\/kp.15163","author":"A S\u0142owik","year":"2020","unstructured":"S\u0142owik A, Jagielski P, Potocki P, et al. Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study. Kardiol Pol. 2020. https:\/\/doi.org\/10.33963\/kp.15163.","journal-title":"Kardiol Pol"},{"key":"332_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3956","author":"M Lee","year":"2021","unstructured":"Lee M, Chung WB, Lee JE, et al. Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. Cancer Med. 2021. https:\/\/doi.org\/10.1002\/cam4.3956.","journal-title":"Cancer Med"},{"key":"332_CR13","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.3395","author":"L Livi","year":"2021","unstructured":"Livi L, Barletta G, Martella F, et al. Cardioprotective Strategy for Patients With Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial. JAMA Oncol. 2021. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3395.","journal-title":"JAMA Oncol"},{"key":"332_CR14","doi-asserted-by":"publisher","DOI":"10.31557\/apjcp.2021.22.9.2847","author":"A Wihandono","year":"2021","unstructured":"Wihandono A, Azhar Y, Abdurahman M, Hidayat S. The Role of Lisinopril and Bisoprolol to Prevent Anthracycline Induced Cardiotoxicity in Locally Advanced Breast Cancer Patients. Asian Pacific journal of cancer prevention\u202f: APJCP. 2021. https:\/\/doi.org\/10.31557\/apjcp.2021.22.9.2847.","journal-title":"Asian Pacific journal of cancer prevention : APJCP"},{"key":"332_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.06.023","author":"MG Kaya","year":"2013","unstructured":"Kaya MG, Ozkan M, Gunebakmaz O, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013. https:\/\/doi.org\/10.1016\/j.ijcard.2012.06.023.","journal-title":"Int J Cardiol"},{"key":"332_CR16","doi-asserted-by":"publisher","DOI":"10.5603\/CJ.a2013.0150","author":"A Elitok","year":"2014","unstructured":"Elitok A, Oz F, Cizgici AY, et al. Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up. Cardiol J. 2014. https:\/\/doi.org\/10.5603\/CJ.a2013.0150.","journal-title":"Cardiol J"},{"key":"332_CR17","doi-asserted-by":"publisher","DOI":"10.1159\/000442722","author":"A Tashakori Beheshti","year":"2016","unstructured":"Tashakori Beheshti A, Mostafavi Toroghi H, Hosseini G, et al. Carvedilol Administration Can Prevent Doxorubicin-Induced Cardiotoxicity: A Double-Blind Randomized Trial. Cardiology. 2016. https:\/\/doi.org\/10.1159\/000442722.","journal-title":"Cardiology"},{"key":"332_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/fjc.0000000000000470","author":"M Nabati","year":"2017","unstructured":"Nabati M, Janbabai G, Baghyari S, Esmaili K, Yazdani J. Cardioprotective Effects of Carvedilol in Inhibiting Doxorubicin-induced Cardiotoxicity. J Cardiovasc Pharmacol. 2017. https:\/\/doi.org\/10.1097\/fjc.0000000000000470.","journal-title":"J Cardiovasc Pharmacol"},{"key":"332_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.049","author":"MS Avila","year":"2018","unstructured":"Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, Jr., et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial. J Am Coll Cardiol. 2018. https:\/\/doi.org\/10.1016\/j.jacc.2018.02.049.","journal-title":"J Am Coll Cardiol"},{"key":"332_CR20","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S166481","author":"F Cochera","year":"2018","unstructured":"Cochera F, Dinca D, Bordejevic DA, et al. Nebivolol effect on doxorubicin-induced cardiotoxicity in breast cancer. Cancer management and research. 2018. https:\/\/doi.org\/10.2147\/cmar.S166481.","journal-title":"Cancer management and research"},{"key":"332_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcha.2020.100575","author":"J Wibawa Martha","year":"2020","unstructured":"Wibawa Martha J, Soedarsono DA, Iqbal M, et al. The effect of prophylactic carvedilol on subclinical left ventricular dysfunction after 1 cycle FAC chemotherapy in breast cancer patients. International journal of cardiology Heart & vasculature. 2020. https:\/\/doi.org\/10.1016\/j.ijcha.2020.100575.","journal-title":"International journal of cardiology Heart & vasculature"},{"key":"332_CR22","doi-asserted-by":"publisher","DOI":"10.1177\/1074248418821721","author":"M Nabati","year":"2019","unstructured":"Nabati M, Janbabai G, Esmailian J, Yazdani J. Effect of Rosuvastatin in Preventing Chemotherapy-Induced Cardiotoxicity in Women With Breast Cancer: A Randomized, Single-Blind, Placebo-Controlled Trial. J Cardiovasc Pharmacol Ther. 2019. https:\/\/doi.org\/10.1177\/1074248418821721.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"332_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.102130","author":"AL Mohamed","year":"2024","unstructured":"Mohamed AL, El-Abd AA, Mohamed HG, Noufal AM, Hennawy BS. Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity: A Three Dimentional Echocardiography Study. Curr Probl Cardiol. 2024. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.102130.","journal-title":"Curr Probl Cardiol"},{"key":"332_CR24","doi-asserted-by":"publisher","unstructured":"Wang P, Zhang S, Zhang XB et al. [Protective effect of dexrazoxane on cardiotoxicity in breast cancer patients who received anthracycline-containing chemotherapy]. Zhonghua zhong liu za zhi [Chinese journal of oncology]. 2013; https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3766.2013.02.013.","DOI":"10.3760\/cma.j.issn.0253-3766.2013.02.013"},{"key":"332_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/maj.0000000000000432","author":"F Sun","year":"2015","unstructured":"Sun F, Qi X, Geng C, Li X. Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity. Am J Med Sci. 2015. https:\/\/doi.org\/10.1097\/maj.0000000000000432.","journal-title":"Am J Med Sci"},{"key":"332_CR26","doi-asserted-by":"publisher","DOI":"10.2165\/11632530-000000000-00000","author":"H Zhang","year":"2012","unstructured":"Zhang H, Shen WS, Gao CH, Deng LC, Shen D. Protective effects of salidroside on epirubicin-induced early left ventricular regional systolic dysfunction in patients with breast cancer. Drugs R&D. 2012. https:\/\/doi.org\/10.2165\/11632530-000000000-00000.","journal-title":"Drugs R&D"},{"key":"332_CR27","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12429","author":"FJ Broeyer","year":"2014","unstructured":"Broeyer FJ, Osanto S, Suzuki J, et al. Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients. Br J Clin Pharmacol. 2014. https:\/\/doi.org\/10.1111\/bcp.12429.","journal-title":"Br J Clin Pharmacol"},{"key":"332_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2022.01.008","author":"NA El-Bassiouny","year":"2022","unstructured":"El-Bassiouny NA, Helmy MW, Hassan MAE, Khedr GA. The Cardioprotective Effect of Vitamin D in Breast Cancer Patients Receiving Adjuvant Doxorubicin Based Chemotherapy. Clin Breast Cancer. 2022. https:\/\/doi.org\/10.1016\/j.clbc.2022.01.008.","journal-title":"Clin Breast Cancer"},{"key":"332_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-022-07124-0","author":"RH Werida","year":"2022","unstructured":"Werida RH, Elshafiey RA, Ghoneim A, Elzawawy S, Mostafa TM. Role of alpha-lipoic acid in counteracting paclitaxel- and doxorubicin-induced toxicities: a randomized controlled trial in breast cancer patients. Supportive care in cancer\u202f: official journal of the Multinational Association of Supportive Care in Cancer. 2022. https:\/\/doi.org\/10.1007\/s00520-022-07124-0.","journal-title":"Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer"},{"key":"332_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/10781552231171114","author":"I Moustafa","year":"2024","unstructured":"Moustafa I, Connolly C, Anis M, et al. A prospective study to evaluate the efficacy and safety of vitamin E and levocarnitine prophylaxis against doxorubicin-induced cardiotoxicity in adult breast cancer patients. J Oncol Pharm Pract. 2024. https:\/\/doi.org\/10.1177\/10781552231171114.","journal-title":"J Oncol Pharm Pract"},{"key":"332_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/000331970305400212","author":"D Tallarico","year":"2003","unstructured":"Tallarico D, Rizzo V, Di Maio F, et al. Myocardial cytoprotection by trimetazidine against anthracycline-induced cardiotoxicity in anticancer chemotherapy. Angiology. 2003. https:\/\/doi.org\/10.1177\/000331970305400212.","journal-title":"Angiology"},{"key":"332_CR32","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1007-9572.2016.07.012","author":"SW Zhang","year":"2016","unstructured":"Zhang SW, Zhang XX, Shi ZC. Heart Protective Effect of Carvedilol Combined With Trimetazidine on Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy. Chinese General Practice. 2016. https:\/\/doi.org\/10.3969\/j.issn.1007-9572.2016.07.012.","journal-title":"Chinese General Practice"},{"key":"332_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40061-4","author":"N Osataphan","year":"2023","unstructured":"Osataphan N, Phrommintikul A, Leemasawat K, et al. Effects of metformin and donepezil on the prevention of doxorubicin-induced cardiotoxicity in breast cancer: a randomized controlled trial. Sci Rep. 2023. https:\/\/doi.org\/10.1038\/s41598-023-40061-4.","journal-title":"Sci Rep"},{"key":"332_CR34","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01305-4","author":"MA Serageldin","year":"2023","unstructured":"Serageldin MA, Kassem AB, El-Kerm Y, et al. The Effect of Metformin on Chemotherapy-Induced Toxicities in Non-diabetic Breast Cancer Patients: A Randomised Controlled Study. Drug Saf. 2023. https:\/\/doi.org\/10.1007\/s40264-023-01305-4.","journal-title":"Drug Saf"},{"key":"332_CR35","doi-asserted-by":"publisher","DOI":"10.20996\/1819-6446-2017-13-2-184-190","author":"YV Vasyuk","year":"2017","unstructured":"Vasyuk YV, Nesvetov VV, Shkolnik EL, et al. Possibilities of Ivabradine, a Selective Inhibitor of Ion F-Channels of Sinus Node, in Prevention of Anthracycline Cardiotoxicity in Patients with Breast Cancer. Rational Pharmacotherapy in Cardiology. 2017. https:\/\/doi.org\/10.20996\/1819-6446-2017-13-2-184-190.","journal-title":"Rational Pharmacotherapy in Cardiology"},{"key":"332_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2010.01.019","author":"RA Carvalho","year":"2010","unstructured":"Carvalho RA, Sousa RP, Cadete VJ, et al. Metabolic remodeling associated with subchronic doxorubicin cardiomyopathy. Toxicology. 2010. https:\/\/doi.org\/10.1016\/j.tox.2010.01.019.","journal-title":"Toxicology"},{"key":"332_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae188","author":"X Zhou","year":"2024","unstructured":"Zhou X, Liu Y, Shen Y, et al. Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1\u03b1. Eur Heart J. 2024. https:\/\/doi.org\/10.1093\/eurheartj\/ehae188.","journal-title":"Eur Heart J"},{"key":"332_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0040424","author":"X Zhou","year":"2012","unstructured":"Zhou X, Li C, Xu W, Chen J. Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation. PLoS ONE. 2012. https:\/\/doi.org\/10.1371\/journal.pone.0040424.","journal-title":"PLoS ONE"},{"key":"332_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/ehaa946.0880","author":"MG Delle Donne","year":"2020","unstructured":"Delle Donne MG, Iannielli A, Capozza P, De Caterina R, Marzilli M. Cardioprotective effect of Trimetazidine in patients with early breast cancer receiving anthracycline-based chemotherapy. Eur Heart J. 2020. https:\/\/doi.org\/10.1093\/ehjci\/ehaa946.0880.","journal-title":"Eur Heart J"},{"key":"332_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2023-002579","author":"S Nassiri","year":"2024","unstructured":"Nassiri S, Van de Bovenkamp AA, Remmelzwaal S, et al. Effects of trimetazidine on heart failure with reduced ejection fraction and associated clinical outcomes: a systematic review and meta-analysis. Open heart. 2024. https:\/\/doi.org\/10.1136\/openhrt-2023-002579.","journal-title":"Open heart"},{"key":"332_CR41","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.118.249235","author":"P Menna","year":"2018","unstructured":"Menna P, Calabrese V, Armento G, et al. Pharmacology of Cardio-Oncology: Chronotropic and Lusitropic Effects of B-Type Natriuretic Peptide in Cancer Patients with Early Diastolic Dysfunction Induced by Anthracycline or Nonanthracycline Chemotherapy. J Pharmacol Exp Ther. 2018. https:\/\/doi.org\/10.1124\/jpet.118.249235.","journal-title":"J Pharmacol Exp Ther"},{"key":"332_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.euje.2005.04.009","author":"S Tassan-Mangina","year":"2006","unstructured":"Tassan-Mangina S, Codorean D, Metivier M, et al. Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study. Eur J Echocardiogr. 2006. https:\/\/doi.org\/10.1016\/j.euje.2005.04.009.","journal-title":"Eur J Echocardiogr"},{"key":"332_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv357","author":"F Shaikh","year":"2016","unstructured":"Shaikh F, Dupuis LL, Alexander S, et al. Cardioprotection and Second Malignant Neoplasms Associated With Dexrazoxane in Children Receiving Anthracycline Chemotherapy: A Systematic Review and Meta-Analysis. J Natl Cancer Inst. 2016. https:\/\/doi.org\/10.1093\/jnci\/djv357.","journal-title":"J Natl Cancer Inst"},{"key":"332_CR44","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-020-01146-6","author":"A Alizadehasl","year":"2021","unstructured":"Alizadehasl A, Ghadimi N, Kaveh S, et al. Prevention of anthracycline-induced cardiotoxicity: a systematic review and network meta-analysis. Int J Clin Pharm. 2021. https:\/\/doi.org\/10.1007\/s11096-020-01146-6.","journal-title":"Int J Clin Pharm"},{"key":"332_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173890","author":"RI Mincu","year":"2021","unstructured":"Mincu RI, Lampe LF, Mahabadi AA, et al. Left Ventricular Diastolic Function Following Anthracycline-Based Chemotherapy in Patients with Breast Cancer without Previous Cardiac Disease-A Meta-Analysis. J Clin Med. 2021. https:\/\/doi.org\/10.3390\/jcm10173890.","journal-title":"J Clin Med"},{"key":"332_CR46","doi-asserted-by":"publisher","DOI":"10.1007\/s12012-016-9365-z","author":"G Janbabai","year":"2017","unstructured":"Janbabai G, Nabati M, Faghihinia M, et al. Effect of Enalapril on Preventing Anthracycline-Induced Cardiomyopathy. Cardiovasc Toxicol. 2017. https:\/\/doi.org\/10.1007\/s12012-016-9365-z.","journal-title":"Cardiovasc Toxicol"},{"key":"332_CR47","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-018-9755-3","author":"S Huang","year":"2019","unstructured":"Huang S, Zhao Q, Yang ZG, et al. Protective role of beta-blockers in chemotherapy-induced cardiotoxicity-a systematic review and meta-analysis of carvedilol. Heart Fail Rev. 2019. https:\/\/doi.org\/10.1007\/s10741-018-9755-3.","journal-title":"Heart Fail Rev"},{"key":"332_CR48","doi-asserted-by":"publisher","unstructured":"Noel CV, Rainusso N, Robertson M et al. Early detection of myocardial changes with and without dexrazoxane using serial magnetic resonance imaging in a pre-clinical mouse model. Cardio-oncology (London, England). 2021; https:\/\/doi.org\/10.1186\/s40959-021-00109-8.","DOI":"10.1186\/s40959-021-00109-8"},{"key":"332_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(10)70204-7","author":"SE Lipshultz","year":"2010","unstructured":"Lipshultz SE, Scully RE, Lipsitz SR, et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010. https:\/\/doi.org\/10.1016\/s1470-2045(10)70204-7.","journal-title":"Lancet Oncol"},{"key":"332_CR50","doi-asserted-by":"publisher","unstructured":"Rossetto L, Di Lisi D, Madaudo C et al. Right ventricle involvement in patients with breast cancer treated with chemotherapy. Cardio-oncology (London, England). 2024; https:\/\/doi.org\/10.1186\/s40959-024-00224-2.","DOI":"10.1186\/s40959-024-00224-2"},{"key":"332_CR51","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-023-02897-9","author":"D Di Lisi","year":"2023","unstructured":"Di Lisi D, Manno G, Madaudo C, et al. Chemotherapy-related cardiac dysfunction: the usefulness of myocardial work indices. Int J Cardiovasc Imaging. 2023. https:\/\/doi.org\/10.1007\/s10554-023-02897-9.","journal-title":"Int J Cardiovasc Imaging"},{"key":"332_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-024-01059-9","author":"M Camilli","year":"2025","unstructured":"Camilli M, Viscovo M, Maggio L, et al. Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond. Basic Res Cardiol. 2025. https:\/\/doi.org\/10.1007\/s00395-024-01059-9.","journal-title":"Basic Res Cardiol"},{"key":"332_CR53","doi-asserted-by":"publisher","DOI":"10.1097\/fjc.0000000000000586","author":"AE El-Naggar","year":"2018","unstructured":"El-Naggar AE, El-Gowilly SM, Sharabi FM. Possible Ameliorative Effect of Ivabradine on the Autonomic and Left Ventricular Dysfunction Induced by Doxorubicin in Male Rats. J Cardiovasc Pharmacol. 2018. https:\/\/doi.org\/10.1097\/fjc.0000000000000586.","journal-title":"J Cardiovasc Pharmacol"},{"key":"332_CR54","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11887","author":"TG Neilan","year":"2023","unstructured":"Neilan TG, Quinaglia T, Onoue T, et al. Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial. JAMA. 2023. https:\/\/doi.org\/10.1001\/jama.2023.11887.","journal-title":"JAMA"},{"key":"332_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.07.016","author":"M Camilli","year":"2024","unstructured":"Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM. Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncology. 2024. https:\/\/doi.org\/10.1016\/j.jaccao.2024.07.016.","journal-title":"JACC CardioOncology"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00332-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00332-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00332-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T07:03:23Z","timestamp":1751871803000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-025-00332-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["332"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00332-7","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"14 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable, as this study is based on publicly available data from previously published studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}